Introduction
Surgical resection is the only potentially curative treatment for benign and borderline neoplasms of the pancreas. Robot-assisted enucleation provides the dual benefits of a minimally-invasive technique and pancreatic parenchymal conservation to selected patients with functional neuroendocrine tumors (pNETs) and serous cystadenomas. This review describes the technique of robot-assisted enucleation with an up to date description of indications, patient selection, pre-operative evaluation, and postoperative outcomes. tumor size alone (3, 4) . Insulinoma is the most common functional neuroendocrine tumor of the pancreas and are ideal candidates for enucleation when <2 cm given 80% probability that such lesions are benign (5, 6) .
Whereas most insulinomas are benign, other functional pancreatic neuroendocrine tumors such as gastrinomas, VIPomas, glucagonomas, and somatostatinomas have a higher incidence of malignancy and are more controversial targets for enucleation. Preoperative staging is necessary to rule out local invasion or metastasis. Contrast-enhanced CT and MRI detect liver metastasis with 94% sensitivity and demonstrate tumor number and location as well as distance to the main pancreatic duct. Sensitivity ranges between 55-78% for smaller lesions like insulinomas and gastrinomas (4, 7, 8) . Although endoscopic ultrasound (EUS) detects small lesions with a sensitivity of approximately 90% and permits cytological confirmation, the radial detector provides less useful anatomic localization for operative planning (9) . Somatostatin receptor-based PET scan can be used to detect metastatic insulinoma and guide medical treatment with somatostatin analogues (2) . Specialized studies including arterial calcium stimulation and hepatic venous sampling are now used only sporadically to localize lesions that cannot be identified on imaging studies (10) .
Enucleation of nonfunctional pancreatic neuroendocrine tumors (NF-pNETs) should be approached with greater caution (11) . Triponez et al. reported a correlation between the size of NF-pNETs and the risk of distant metastases, rising from 4% for lesions ≤1 cm, 10% between 1.1-2 cm, and 43% when the tumor was >3 cm (6) . Current guidelines do not recommend enucleation for NF-pNETs >1-2 cm or for lesions <1 cm with significant growth in the prior 3-6 months (4).
Currently, pNETs share the same TNM/AJCC staging system with pancreatic exocrine tumors albeit with significantly better survival outcomes. The World Health Organization (WHO) recommends histological grading of gastroenteropancreatic neuroendocrine tumors according to mitotic rate and Ki-67 index (2) . Current evidence reserves enucleation for lesions meeting specific characteristics ( Table 1) .
Evaluation for hormonal activity
Approximately 30-80% of patients with MEN1 syndrome harbor functional pNETs (4), which may be multifocal. Distinguishing sporadic pNET from MEN1 is critical since MEN1 patients may harbor multifocal disease for which medical management is initially indicated (2) . Clinical suspicion for MEN1 requires assessment for multi-gland parathyroid hyperplasia and pituitary tumors (2) .
The preoperative biochemical evaluation should be guided by the suspected clinical syndrome. Insulin and gastrin (Zollinger-Ellison syndrome, ZES) are the most common hormones produced by F-pNETs. Insulinomas typically present with symptoms of neuroglycopenia associated with high insulin (>3 mcIU/mL) levels, elevated C-peptide (>0.6 ng/mL) and proinsulin concentrations (>5 pmol/L) (6) during fasting hypoglycemia (<55 mg/dL). Insulinomas are potentially dangerous tumors, and hypoglycemia must be addressed with diet or diazoxide so that localization may be safely obtained (12) . Gastrinomas may present with recurrent peptic ulcers, diarrhea, and steatorrhea and manifest as elevated fasting serum gastrin concentration (>10 times elevated) with abnormal basal gastric acid secretion (pH <2) (6) . Symptoms may be controlled preoperatively with highdose proton pump inhibitors (13) and octreotide as required (14) . 
Technique of robot-assisted enucleation

Patient positioning
The patient is placed on the operating table in a well-padded split leg supine position with a gel-padded foot board. The arm corresponding to the side of the lesion is tucked, and the other arm remains exposed for anesthesia access. 
Operative technique
Step 1: port placement
We enter the peritoneal cavity in the left midclavicular line approximately three fingerbreadths below the costal margin using a 5-mm optical separator. Six-Seven ports are required: a 5 mm port in the right anterior axillary line to secure the liver retractor; a 12 mm port in the right lower quadrant for ultrasound access and needle passage; a 12 mm camera port located in proximity to the tumor, and three 8 mm robotic ports across the upper abdomen, with the two robot arms on the side of the tumor (Figures 1,2 ).
Step 2: exposure
For lesions of the pancreatic head and uncinate process, the lesser sac is divided and a generous Kocher maneuver is performed to expose the pancreatic head and root of the mesentery. The right gastroepiploic vascular pedicle may be divided to expose the medial border of the pancreatic head and uncinate process. Exposure of the superior mesenteric vein may be required to protect it during enucleation of uncinate process lesions and those over the pancreatic neck. For tumors of the pancreatic body/tail, the greater omentum is divided as far to the left as required to gain adequate exposure, which may require dividing the short gastric vessels as well as splenic flexure omentum along the inferior border of the pancreas.
Step 3: localizing the lesion
With the anterior surface of the pancreas in view and the stomach retracted, we dock the robot prior to intraoperative ultrasound. Minimally-invasive enucleation is an imagingdependent procedure that requires recognizable anatomic landmarks for successful completion. Critical information includes tumor proximity to the pancreatic duct as well as localization relative to major structures such as the gastroduodenal artery or bile duct, as well as the portal vein behind the pancreatic neck. Intraoperative palpation is not feasible. Localization often mandates intraoperative ultrasound aided by duplex studies of intratumoral blood flow and frozen section confirmation. We utilize the console's dual visual/ ultrasound image platform to localize the lesion and mark the boundaries of enucleation and to confirm proximity to the main pancreatic duct and adjacent major vascular structures (Figure 3) . The patient cart's bulk effectively precludes intraoperative palpation through a hand access port.
Step 4: enucleating the lesion
The pancreatic parenchyma around the lesion is marked with cautery scissors at the desired margin distance, and a silk suture is used for traction and exposure during dissection. The pancreas is divided sequentially using cautery scissors, with 5-0 Prolene and suction used liberally to maintain visualization of the pseudocapsule which marks the minimal acceptable pathological margin (Figure 4 ).
Step 5: continuity of the pancreatic duct
In the absence of visual evidence that the pancreatic duct has been injured, intraoperative ultrasound is deployed to inspect the deep margin of resection. When in doubt, secretin can be administered while the cavity is observed for signs of a leak. We routinely use a 19 French surgical drain in expectation of a low-output pancreatic fistula.
Post-operative management
An oral diet and pain regimen may be initiated rapidly after minimally-invasive enucleation with expectation of early discharge. Medications, such as diazoxide, used to manage hormone-producing tumors must be adjusted after resection. Surgical drain management is institutiondependent and was not the subject of recent level 1 evidence gathered after pancreaticoduodenectomy or distal pancreatectomy (17) .
Postoperative outcomes
The European Association for Endoscopic Surgery Clinical Consensus (13) 
